This Is MS Multiple Sclerosis Community: Knowledge & Support

A blurb about Campath from a Genzyme press release today:



Following an encouraging meeting with the FDA in November, Genzyme expects to initiate during the first half of this year a phase 3 study of alemtuzumab (Campath) for the treatment of relapsing/remitting multiple sclerosis. The company is currently developing the study protocol to submit to the agency for review. Two-year results from a pre-planned interim analysis of the three-year phase 2 study were released in September and showed a robust, statistically significant treatment effect for alemtuzumab compared with Rebif(R) (interferon beta-1a). The IND for this trial remains on clinical hold in the United States, and Genzyme is working closely with clinical investigators and regulatory agencies to complete the study and ensure that the risk of immune thrombocytopenic purpura (ITP) is well understood and managed. Genzyme has implemented a comprehensive risk management plan to help physicians and patients participating in the trial detect ITP early and minimize the risk of complications.

http://www.drugnewswire.com/11163/

Thanks dignan, always good to hear about something hopeful progressing!

I couldn't get the link to work but I assume that it basically was the same information that you pasted to the post?
Bob

The link doesn't contain any more info about Campath for MS, it's just got more corporate updates from Genzyme. Don't know what to say about the link, it works for me.

Thanks for the info.
Nope, I don't think it was a bad link, just server trouble. When I clicked on it I connected to the site but nothing would load. I tried twice in the space of a few minutes, their server might be working properly now.

Thanks,
Bob